• English
  • 简体中文
Login Register
Current Location: Home > Marketing Drugs(EU) Feedback Help Print
Product No EMEA/H/C/002455
Brand Name Adcetris
Nonproprietary Name brentuximab vedotin
API brentuximab vedotin
ATC Code L01XC12
Indications Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): following autologous stem-cell transplant (ASCT) or; following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. Adcetris is indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large-cell lymphoma (sALCL).
Orphan Drug yes
Generics no
Marketing Authorization Holder Takeda Pharma A/S
Status Authorised
Authorization Date 2012-10-25
Version 12
Condition Approval yes
Exceptions no
Biosimilar no
Details 查看 (公众评估报告、授权细节、产品规格/剂型、标签、历史评估信息)